Diversity and biofilm-production ability among isolates of *Escherichia coli* phylogroup D belonging to ST69, ST393 and ST405 clonal groups

Ángela Novais¹*, Claudia Vuotto², João Pires¹, Carolina Montenegro¹, Gianfranco Donelli², Teresa M Coque³ and Luísa Peixe¹

Abstract

**Background:** Phylogenetic group D *Escherichia coli* clones (ST69, ST393, ST405) are increasingly reported as multidrug resistant strains causing extra-intestinal infections. We aim to characterize inter- and intraclonal diversity of a broad sample (isolates from different geographic locations and origins with variable antibiotic resistance profiles, 1980-2010) and their ability to adhere and form biofilm by both a modified quantitative biofilm producing assay and Field Emission Scanning Electron Microscopy (FESEM).

**Results:** High virulence scores were observed among ST69 (median 14/range 9–15) and ST393 (median 14/range 8–15) clones, particularly enriched in *pap* alleles, *iha*, *kpsMTII*-K5 and *ompT*, in contrast with ST405 (median 6/range 2–14) isolates, exhibiting frequently *fyuA*, *malX* and *traT*. All ST69 and ST393 and only two ST405 isolates were classified as ExPEC. Biofilm production was detected in two non-clinical ST69 and three ST393 isolates from different origins showing variable virulence profiles. Within each clonal group, and despite the high diversity of PFGE-types observed, isolates from different countries and recovered over large periods of time were clustered in a few groups sharing common virulence gene profiles among ST69 (n = 10 isolates) and ST393 (n = 9 isolates) (*fimH*-iha-iutA-*kpsMTII*-K5-(traT)-sat-(ompT)-*papA*-papEF-papGII-*papC*) or ST405 (n = 6 isolates) (*fimH*-traT-*fyuA*-malX).

**Conclusions:** This study highlights the circulation of highly transmissible ST69, ST393 and ST405 variants among different settings. Biofilm production seems not to be directly correlated with their epidemiological success.

**Keywords:** ExPEC, High-risk clones, ESBL, Virulence, Adhesion, Biofilm

Background

Multidrug resistant *Escherichia coli* clones of the phylogenetic group D causing extraintestinal human infections are increasingly reported all over the world [1-4]. Among them, *E. coli* clonal groups D-ST69 (also recognized as clonal group A or CGA) and D-ST393 (also known as O15:K52:H1 clonal group) are widely spread among different hosts, often causing urinary tract infections (UTI) and conferring resistance to antibiotics [5-10]. Isolates belonging to the D-ST405 have been involved in the spread of genes encoding extended spectrum β-lactamas (ESBLs) (mainly CTX-M enzymes), cephamycinases (AmpC), carbapenemases (NDM) or methylases (AmrA, RmtB) [2,11-15]. Recent studies have reported variants of ST69, ST393 and ST405 among ESBL and non-ESBL-producing strains from specific locations [4,5,8,9,13,16]. The presence of genes possibly involved in biofilm production detected in some of these surveys (*fimH*, *papC*, *papG*, *fyuA* or *kpsMT II*) suggests the ability of these clones to adhere and form biofilm, which could be favouring their persistence; however, such ability has not been specifically evaluated [5,8,13,17,18]. Biofilm growing ability of bacteria is commonly assessed by a quantitative measure of their adherence to microtiter plates, although electron microscopy analyses provide more accurate information on the biofilm structure and presence of matrix [17-19].

* Correspondence: angelasilvanovais@gmail.com
¹Departamento de Microbiologia, REQUIMTE, Faculdade Farmácia Universidade Porto, Rua Jorge Viterbo Ferreira nº 228, 4050-313 Porto, Porto, Portugal
Full list of author information is available at the end of the article

© 2013 Novais et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
In this study, we aim to characterize the intraclonal diversity of extraintestinal pathogenic *E. coli* (ExPEC) isolates from phylogenetic group D (ST69, ST393, ST405) isolated from different geographic locations and sources, and to assess their ability to adhere and form biofilm on abiotic surfaces in order to evidence a possible contribution of biofilm formation to their persistence and epidemicity.

**Methods**

**Bacterial isolates**

We analysed thirty-five *E. coli* isolates belonging to ST69 (n = 13), ST393 complex (10 ST393, 1 ST2321) and ST405 complex (10 ST405, 1 ST964) isolated from multiple sources and countries. They include either isolates associated with nosocomial or community outbreaks in different countries [2,4,9,12,20] or isolates collected from non-clinical sources from distinct countries and showing variable antibiotic resistance profiles, selected from published papers by the end of 2010. They were recovered from nosocomial (66%) and community-acquired infections (17%), healthy volunteers (8%), food products (6%) or animals (3%) and produced diverse ESBL or AmpC enzymes. Their epidemiological features are shown in Table 1. Isolates were taken as part of standard patient care and no ethical approval was required for their use.

**Clonal diversity**

Relatedness among isolates was established by XbaI-pulsed-field gel electrophoresis (PFGE), multi-locus sequence typing (MLST, http://mlst.ucc.ie/mlst/dbs/Ecoli), and identification of *E. coli* phylogenetic groups and serogroups by PCR [28]. Isolates exhibiting ≥85% homology were considered to belong to the same PFGE-type. XbaI-profiles were compared using InfoQuest® FP version 5.4 software (BioRad Laboratories), by applying the UPGMA algorithm based on the Dice coefficient (1.0% band tolerance; 1.0% optimization).

**Virulence genes profile**

Screening of 38 virulence factors (VFs) including adhesins, toxins, siderophores, polysaccharide coatings and others (*malX, usp, ibeA, iss, tsh*) presumptively associated with ExPEC isolates was performed by PCR as previously described [8,28]. The Fisher’s exact test was used for each comparison, a *p* value < 0.05 being considered to reveal significant differences. A strain satisfied the criteria for being ExPEC if it carried two or more of the following genes: *papA, papC, sfa/focDE, afa/draBC, iutA* and *kpsMII* [8].

**Adhesion and biofilm-producing assays**

The ability of D-*E. coli* strains to *in vitro* adhere was investigated by a modified quantitative biofilm production assay, as previously described [28]. The *E. coli* strain CFT073 and the culture medium supplemented with 1% (v/v) glucose were used as positive and negative controls, respectively. Assays were performed in quintuplicate and repeated at least 4 times. The cut-off optical density (ODc) was defined as three standard deviations above the mean OD of the negative control (culture medium), and strains were classified as non-adherent (OD ≤ ODc), weakly adherent (ODc < OD ≤ 2 × ODc), moderately adherent (2 × ODc < OD ≤ 4 × ODc), or strongly adherent (OD > 4 × ODc). The ultrastructural analysis of biofilm was performed by a Field Emission Scanning Electron Microscope (FESEM) (Zeiss, Germany). Briefly, adjusted inocula (200 μl, 0.5 McF) of each strain diluted with 1.8 ml of fresh LB supplemented with 1% (v/v) glucose were added to 24-well plates with round glass coverslips (1 cm diameter) put into each well and incubated at 37°C for 24 h. The content of each well was removed and the round coverslips were washed with PBS (1%) twice. Biofilms grown on coverslips were fixed with 2.5% glutaraldehyde in Na-cacodylate 0.1 M (pH 7.4) buffer solution (AppliChem, Germany) for 2 h at room temperature. Following three washing steps with the same buffer solution, samples were dehydrated through graded ethanol (30°, 50°, 70°, 85°, 95°, 100°) and dried with hexamethyldisilazane (Alfa Aesar, USA) for 1 h. Samples were air-dried overnight and coated by sputtering with a gold target [19].

**Results and discussion**

**Diversity among clonal groups of *E. coli* phylogroup D**

Isolates belonging to the three analysed STs exhibited inter and intraclonal variability regarding the VF profile and the ability to form biofilm. On the basis of their virulence scores, all ST69 (n = 13/13; median = 14/range = 9-15) and all ST393 (n = 11/11; median = 14/range = 8-15), and only sporadic ST405 (n = 2/11; median = 6/range = 2-14) isolates were classified as ExPEC (Table 2). While most ST69 and ST393 carried *pap* alleles (*papA, papC, papEF, papGII*), *iha, kpsMII-K5* and *ompT*, ST405 isolates frequently contained *fyuA, malX* and *traT*, suggesting the presence of different genomic islands among *E. coli* phylogroup D isolates.

Most of the isolates exhibited a weak adherence ability to abiotic surfaces (9 ST69, 8 ST393, 9 ST405; 0.13 < OD < 0.27) while a few strains were classified as moderately adherent (3 ST393, 2 ST69 and 1 ST405; 0.29 < OD < 0.47) or strongly adherent (2 ST69, 1 ST405; 0.49 < OD < 0.71) (Figure 1), and were considered as presumptive biofilm producers. Among all the strains resulting to be moderately or strongly adherent, FESEM observations revealed the presence of aggregates and EPS matrix, both compatible with a biofilm development, only in two ST69 (69PT1S, 69PT2S) and three ST393 (393FR3E, 393N1H, 2321PT1H) isolates (Figure 2). These isolates corresponded...
Table 1 Epidemiological data and diversity among ST69, ST393 and ST405 clonal groups

| ST (N°) | Serotype | PFGE-type (Cluster) | Country (N° isolates) | Date       | Origin* (N° isolates) | ESBL / AmpC | Antibiotic resistance profileb | Virulence gene profileb | Reference |
|---------|----------|---------------------|-----------------------|------------|-----------------------|-------------|-------------------------------|------------------------|-----------|
| 69      | O11, O73, O77 | 69_1 (I) | US (4), NW (1) | 1999-2002 | H Urine (3), blood (2) | (Cm), Sm, Su, (Te), Tp, Ts | fimH, iha, iutA, kpsMTII, KS, traT, sat, ompT, (fyuA), papA, papEF, papGII, papC, papGII | iroN, (iss), (iexA) | [20,21] |
| 69      | O77      | 69_2 (I) | SP (1) | - | H Urine | - | Sm, Su, Te, Tp, Ts | fimH, iha, iutA, kpsMTII, KS, traT, sat, ompT, (fyuA), papA, papEF, papGII, papC, papGII | | [20] |
| 69      | -        | 69_3 (I) | BR (1) | - | H, C | - | (Ak), Crn, (Gm), (Km), (Nt), Sm, Su, (Tb), Te, Tp, Ts | fimH, iha, iutA, kpsMTII, KS, traT, sat, ompT, (fyuA), papA, papEF, papGII, papC | | [12,22] |
| 69      | -        | 69_4 (I) | PT (1) | 2007 | H Urine | - | Crn, Na, Sm, Su, Tp, Tp | fimH, iha, iutA, kpsMTII, KS, traT, sat, ompT, (fyuA), papA, papEF, papGII, papC | This study | |
| 69      | O17      | 69_5 (I) | US (1) | - | H Blood | - | Crn, Sm, Su, Te, Tp, Ts | fimH, iha, iutA, kpsMTII, KS, traT, sat, ompT, papA, papEF, papGII, papC, papGII | | [20] |
| 69      | -        | 69_6 (II) | PT (2) | 2010 | S | - | Km, Sm, Su, Te, Tp, Ts | fimH, iha, iutA, kpsMTII, KS, traT, (ompT), papA, papEF, papC, papGII, bmaE, gadG, iroN, (iss) | | [23] |
| 69      | -        | 69_7 (II) | NW (1) | 2002 | A Poultry meat | - | Sm, Su, Te, Ts | fimH, iha, traT, (ompT), papC, papGII, bmaE, gadG, iroN, (iss) | | [21] |
| 393     | O15      | NA e | US (1) | 1980 | H | - | - | fimH, iha, iutA, kpsMTII, KS, sat, ompT, papA, papEF, papGII, papC | | [4] |
| 393     | O15      | NA d | US (1) | 1998 | H | - | Crn, Gm, Km, Nt, Sm, Su, Tp, Te, Ts | fimH, iha, iutA, kpsMTII, KS, sat,ompT, papA, papEF, papGII, papC | | [4] |
| 393     | O15      | NA b | US (1) | 1999 | H | - | Cp, Km, Na, Sm, Su, Te, Tp, Ts | fimH, iha, iutA, kpsMTII, KS, sat, papA, papEF, papGII, papC, iroN, (iss) | | [4] |
| 393     | O15      | NA a | KO (1) | 2006-07 | C Urine | - | Cp, Gm, Km, Na, Nt, Sm, Su, Tb, Te, Tp, Ts | fimH, iha, iutA, kpsMTII, KS, K1, traT, sat, ompT, papA, papEF, papGII, papC | | [9] |
| 393     | O15      | NA a | FR (1) | 2006 | F Feces | - | Cp, Gm, Km, Na, Nt, Sm, Su, Tb, Te, Tp, Ts | fimH, iha, iutA, kpsMTII, KS, traT, sat, ompT, papA, papEF, papGII, papC, iroN, (iss) | | [24] |
| 393     | Q25      | NA     | FR (1) | 2006 | F Feces | - | Cp, Na, Sm, Su, Te, Tp, Ts | fimH, iha, iutA, kpsMTII, KS, sat, ompT, papA, papEF, papGII, papC, iroN, (iss) | | [24] |
| 393     | O15      | NA a | FR (1) | 2006 | F Feces | - | Crn, Cp, Gm, Km, Nt, Sm, Su, Tb, Te, Tp, Ts | fimH, iha, iutA, kpsMTII, KS, K1, traT, sat, papA, papEF, papGII, papC, iroN, (iss) | | [24] |

* Origin: C: chicken, P: pig, U: unknown

b ESBL: extended-spectrum beta-lactamase, AmpC: Ampicillin-resistant beta-lactamase

References:
[20, 21, 12, 22, 23, 24]
### Table 1 Epidemiological data and diversity among ST69, ST393 and ST405 clonal groups (Continued)

| Isolate | ST | Location | Year | Source | Serotype | CTX-M Type | Resistance Profile | FimH, Iha, IutA, KpsMTII, KS, Sat, papA, papEF, papGII, papC, iss, tsh |
|---------|----|----------|------|--------|----------|------------|-------------------|-----------------------------------------------|
| 393 O15 | NA | SP (1)   | 2002 | C      | Urine    | CTX-M-14    | Cp, Na, Sm, Su, Ts | fimH, iha, iutA, kpsMTII, KS, sat, papA, papEF, papGII, papC, iss, tsh |
| 393 O15 | NA | KO (1)   | 2006-7| C      | Urine    | -          | Cp, Km, Na, Sm, Su, Te, Tp, Ts | fimH, iha, iutA, kpsMTII, KS, papEF, papGII, papC |
| 393 O15 | NA | NW (1)   | 2005 | H      | Urine    | CMY-2      | Cp, Km, Na, Nf, Sm, Su, Tp, Ts | fimH, iutA, kpsMTII, KS, K1, ompT, fyuA, iss, tsh |
| 2321 O25| NA | PT (1)   | 2008 | H      | Urine    | TEM-like   | Cp, Na, Sm, Su, Te, Tp, Ts | fimH, iha, iutA, kpsMTII, KS, K1, sat, fyuA, papEF, papGII, papC, iss, tsh, malX, iroN |
| 405    |    | 405_1 (1)| SP (1), KU (1) | 2002-2004 | H | Wound (1), Urine (1), Respiratory (1) | CTX-M-15 (2), CTX-M-3 (1) | (Cp), Crn, Grm, Km, Na, (Nt), Sm, Su, Tb, Te, Tp, Ts | fimH, iha, iutA, kpsMTII, traT, sat, (malX), fyuA, (kpsMTII), (iss), (tsh) |
| 405    |    | 405_2 (1)| NW (1) | 2003 | H | Wound | CTX-M-14 | Crn, Km, Sm, Su, Te, Tp, Ts | fimH, iutA, kpsMTII |
| 405    |    | 405_3 (1)| NW (1) PT (1) | 2003-2006 | H | Abcess (1), Urine (1) | CMY-2 (1), CTX-M-15 (1) | (Grm), (Km), Na, Sm, Su, (Tb), Te, Tp, Ts | fimH, iha, iutA, (kpsMTII), traT, malX, fyuA, (papEF), (papGII), (iroN), (iss), (tsh), (ireA) |
| 405    |    | 405_4 (1)| SW (1) | SP (1) | 2000-2005 | H, C | Urine (1), Blood (1) | CTX-M-15, TEM-24 | (Cm), Crp, (Grm), Km, Na, (Nt), Sm, Su, Tb, Te, Tp, Ts | fimH, (iutA), traT, malX, fyuA, kpsMTII, (iss), (tsh) |
| 405    |    | 405_5 (1)| SP (1) | 2001 | H | Wound | TEM-52 | Crm, Grp, Grm, Km, Na, Sm, Su, Tb, Te, Ts | traT, fyuA, kpsMTII |
| 405    |    | 405_6 (1)| NA | 2008 | C | Urine | CTX-M-15 | Ak, Crp, Grm, Na, Tb, Ts | fimH, fyuA |
| 405    |    | 405_7 (1)| NW (1) | 2003 | H | Respiratory | CTX-M-15 | Crm, CpgGrm, Km, Na, Nf, Sm, Su, Tb, Te, Tp, Ts | fimH, traT, sat, fyuA, papEF |

**Definitions:**
- **fimH** (type 1 fimbriae), **iha** (iron-regulated-gene-homologue adhesion), **sat** (secreted autotransporter toxin), **tsh** (serine protease autotransporter), **fyuA** (yersiniabactin receptor), **iutA** (ferric aerobactin receptor), **iroN** (catecholate siderophore receptor), **ireA** (iron-regulated element), **kpsMTI** (group I capsular polysaccharide), **kpsMTII K1** (variant K1), **kpsMTII KS** (variant KS), **kpsMTIII** (group III capsular polysaccharide), **traT** (serum survival associated), **iss** (increased serum survival), **usp** (uropathogenic-specific protein), **ompT** (outer membrane protease), **malX** (pathogenicity-associated island marker).

**Abbreviations:**
- **Ak** Amikacin, **Cm** Chloramphenicol, **Cp** Ciprofloxacin, **Gm** Gentamicin, **Km** Kanamycin, **Na** Nalidixic acid, **Nt** Nitelimicin, **Nf** Nitrofurantoin, **Sm** Streptomycin, **Su** Sulphonamides, **Tb** Tobramycin, **Tp** Trimethoprim, **Tm** Trimethoprim-Sulfamethoxazole.

**Definitions:**
- **papA** (P fimbriae major subunit, pyelonephritis-associated), **papC** (P fimbriae assembly), **papEF** (P fimbriae minor tip pilins), **papG** allele I (papG variant), **papG** allele II (papG variant, pyelonephritis-associated), **papG** allele III (P fimbriae adhesion, cystitis-associated), **sfa/focDE** (S and F1C fimbriae), **bmaE** (Blood group M-specific adhesin), **gafD** (glucosamine-specific adhesin), **iha** (iron-regulated-gene-homologue adhesion), **sat** (secreted autotransporter toxin), **tsh** (serine protease autotransporter), **fyuA** (yersiniabactin receptor), **iutA** (ferric aerobactin receptor), **iroN** (catecholate siderophore receptor), **ireA** (iron-regulated element), **kpsMTI** (group I capsular polysaccharide), **kpsMTII K1** (variant K1), **kpsMTII KS** (variant KS), **kpsMTIII** (group III capsular polysaccharide), **traT** (serum survival associated), **iss** (increased serum survival), **usp** (uropathogenic-specific protein), **ompT** (outer membrane protease), **malX** (pathogenicity-associated island marker).
to diverse clonal variants exhibiting variable virulence gene profiles, preventing from establishing a link between this phenotype and a given virulence gene or virulence gene profile.

The presence of a characteristic virulence gene profile for isolates of different *E. coli* clonal groups confirms results obtained in previous studies [5,8]. However, small differences in the virulence profile observed among closely related isolates might be explained by the plasticity of the genomic islands where these genes are commonly clustered [29]. Most of the isolates were associated with extraintestinal infections (n = 25/35; 71%), including the non-ExPEC ST405 isolates. The lack of correspondence between ExPEC status and the ability to cause extraintestinal disease further suggests that other non-explored virulence factors might influence their

| Virulence genes* | ST69 (n = 13) | ST393 (n = 11) | ST405 (n = 11) | ST69 vs ST393 | ST69 vs ST405 | ST393 vs ST405 |
|------------------|---------------|----------------|---------------|---------------|---------------|---------------|
| **Adhesins**     |               |                |               |               |               |               |
| fimH             | 13 (100%)     | 11 (92%)       | 9 (82%)       | 0.480         | 0.199         | 0.590         |
| papA             | 11 (85%)      | 8 (67%)        | 0 (0%)        | 0.378         | 0.000         | 0.001         |
| papC             | 12 (92%)      | 10 (83%)       | 0 (0%)        | 0.593         | 0.000         | 0.000         |
| papEF            | 12 (92%)      | 9 (75%)        | 2 (18%)       | 0.322         | 0.001         | 0.012         |
| papG allele I    | 0 (0%)        | 1 (8%)         | 0 (0%)        | 0.480         | -             | 1.000         |
| papG allele II   | 9 (69%)       | 10 (83%)       | 0 (0%)        | 0.645         | 0.001         | 0.000         |
| papG allele III  | 9 (69%)       | 2 (17%)        | 1 (9%)        | 0.015         | 0.005         | 1.000         |
| bmaE             | 2 (15%)       | 0 (0%)         | 0 (0%)        | 0.480         | 0.482         | -             |
| gatD             | 2 (15%)       | 0 (0%)         | 0 (0%)        | 0.480         | 0.482         | -             |
| iha              | 10 (77%)      | 10 (83%)       | 2 (18%)       | 1.000         | 0.012         | 0.003         |
| **Toxins**       |               |                |               |               |               |               |
| sat              | 10 (77%)      | 9 (75%)        | 6 (55%)       | 1.000         | 0.390         | 0.400         |
| tsh              | 1 (8%)        | 7 (58%)        | 3 (27%)       | 0.011         | 0.300         | 0.214         |
| **Siderophores** |               |                |               |               |               |               |
| fyuA             | 8 (62%)       | 8 (67%)        | 11 (100%)     | 1.000         | 0.041         | 0.093         |
| iutA             | 11 (85%)      | 11 (92%)       | 6 (55%)       | 1.000         | 0.182         | 0.069         |
| iroN             | 5 (39%)       | 1 (8%)         | 1 (9%)        | 0.160         | 0.166         | 1.000         |
| iroA             | 2 (15%)       | 0 (0%)         | 1 (9%)        | 0.480         | 1.000         | 1.000         |
| **Capsule**      |               |                |               |               |               |               |
| kspMT II         | 12 (92%)      | 11 (100%)      | 2 (18%)       | 1.000         | 0.001         | 0.000         |
| kspMT III        | 0 (0%)        | 0 (0%)         | 5 (46%)       | -             | 0.011         | 0.014         |
| K1               | 0 (0%)        | 4 (33%)        | 0 (0%)        | 0.039         | -             | 0.093         |
| K5               | 12 (92%)      | 11 (100%)      | 0 (0%)        | 1.000         | 0.000         | 0.000         |
| **Protectins**   |               |                |               |               |               |               |
| traT             | 13 (100%)     | 3 (25%)        | 10 (91%)      | 0.000         | 0.458         | 0.003         |
| iss              | 5 (39%)       | 6 (50%)        | 3 (27%)       | 0.695         | 0.679         | 0.400         |
| **Miscellaneous**|               |                |               |               |               |               |
| usp              | 1 (8%)        | 0 (0%)         | 0 (0%)        | 1.000         | 1.000         | -             |
| ompT             | 12 (92%)      | 6 (50%)        | 0 (0%)        | 0.030         | 0.000         | 0.014         |
| malX (PAI)       | 0 (0%)        | 1 (8%)         | 7 (64%)       | 0.480         | 0.001         | 0.009         |
| ExPEC statusb    | 12 (100%)     | 11 (100%)      | 2 (18%)       | -             | 0.000         | 0.000         |
| **Virulence score** | 13.23 (± 1.641) | 11.67 (± 3.576) | 6.27 (± 3.197) | 1.000 | 0.007 | 0.053 |
| **Range**        | 9 – 15        | 8 – 15         | 2 – 14        | -             | -             | -             |

*p values (Fisher's exact test) are shown in bold when p < 0.05. ExPEC status defined by the presence of two or more among *papA, papC, sfa/foc, afa/draBC, iutA* and *kpsMTII*, as suggested [8].*
Our results indicate that biofilm production seems not to be directly related with their epidemiological success, as already observed for the pandemic ST131 *E. coli* clone [28]. Moreover, when observed in particular strains, this feature could not be linked to a specific virulence gene or virulence profile.

**Intraclonal diversity of ST69 isolates**

Thirteen isolates corresponding to 7 PFGE types were classified in different serogroups (O11, O17, O73, O77), and clustered in two groups on the basis of the similarity of the *XbaI* restriction profiles. Cluster I comprised closely related isolates (n = 10, 73.8% homology) causing hospital or...
community acquired infections that exhibited a common virulence gene profile (80%, fimH-icha-iutA-kpsMTII-KS-traT-sat-ompT-papA-papEF-papGII-papC). Cluster II (n = 3, 71.8% homology) included two indistinguishable isolates recovered from different samples of ready-to-eat salads in Portugal and from poultry meat in Norway. They differ in the presence of iroN, iss, bmaE (n = 2/3) and qapF (n = 2/3), and the lack of iha, sat and papGII, observed for isolates of cluster I. All ST69 isolates exhibited resistance to streptomycin and trimethoprim-sulfamethoxazole, and they were frequently resistant to tetracycline (85%), and to chloramphenicol (46%). None of the isolates produced ESBL, but one encoded CMY-2.

Isolates belonging to cluster I seem to have been circulating among different continents since at least 1999, as reflects this and other studies [31-33]. Despite of the small sample analysed, differences among ST69 isolates from human and non-human origins suggest independent evolution of particular *E. coli* variants in different hosts.

**Intraclonal diversity of ST393 isolates**

These isolates corresponded to serogroups O15 (n = 9) or O25 (n = 2, one of them corresponding to ST2321, a single locus variant of ST393), and they mainly were biotype C (non-lactose fermenters and maltose fermenters; n = 7, 58.3%), which seem to be more commonly observed than those of biotype A (lactose and maltose fermenters) [4,6,34]. Most isolates analysed (n = 9/75%) were recovered from patients and healthy individuals in France, Spain, Korea and the USA and shared a pool of ten virulence genes (*fimH-icha-iutA-kpsMTII-KS-sat-papA-papEF-papGII-papC*) (Table 1). The ST2321 isolate belonged to O25 serotype and shared eight out of the ten frequent VFs, suggesting a common origin. Most isolates were resistant to trimethoprim-sulfamethoxazole (91%), streptomycin (91%), ciprofloxacin (82%), tetracycline (73%) and nalidixic acid (73%). Resistance against kanamycin (64%), gentamicin (36%), tobramycin (36%), netilmicin (36%) or chloramphenicol (27%) was also observed. ESBL or AmpC production was sporadically detected (1 CTX-M-14, 1 TEM-like and 1 CMY-2).

The study highlights the spread of ST393 isolates of biotype C with highly similar virulence gene profile in different continents over almost three decades, supporting previous observations in specific countries [5,8]. Unfortunately, clonal relatedness among different strains could not be analysed due to the spontaneous lysis of DNA, also reported by other groups [6,34].

**Intraclonal diversity of ST405 isolates**

Isolates of this clonal complex (n = 11, 6 PFGE types) were recovered from human infections (82% hospital, 18% community), and exhibited a common virulence profile (*fimH-traT-fyuA-malX*, n = 6, 55%) (Table 1). Most isolates belonging to cluster I (n = 6, 2 ExPEC; 77% homology) identified in hospitalized patients from Portugal, Spain, Norway and Kuwait contained additionally *iutA* and *sat* (n = 5/6, 83%) whereas cluster II (n = 3 from Spain and Switzerland; 80% homology) showed consistently *kpsMTIII* but not *iutA* and *sat*. Cluster III comprised only one isolate from Norway corresponding to a single locus variant of ST405 (ST964). ST405 isolates were commonly resistant to streptomycin, sulphonamides, trimethoprim (91% each), kanamycin, tetracycline, nalidixic acid (82% each), gentamicin (73%), tobramycin (64%), ciprofloxacin (45%) and chloramphenicol (45%) (Table 1).

These results suggest that several ST405 variants seem to be circulating in distinct countries. In contrast with ST69 and ST393, isolates frequently produced either ESBLs (mostly CTX-M-15, but also CTX-M-3, CTX-M-14, TEM-24 or TEM-52) or AmpC (CMY-2) enzymes, which might have facilitated the selection and successful spread of diverse ST405 variants [2,13,14,35].

**Conclusion**

Factors responsible for the increased ability of particular *E. coli* clones to successfully spread and persist are poorly understood, and our work represents one of the few studies exploring the phenotypic traits involved in the increased epidemicity of emerging antibiotic resistant *E. coli* clonal groups [28,36]. The results highlight the inter and intraclonal diversity of *E. coli* clones of phylogroup D and further suggest the circulation of highly transmissible ST69, ST393 and ST405 variants, some of them being particularly widespread in different geographic areas and settings. The lack of association between the ability to produce biofilm exhibited by a few strains and specific virulence gene or virulence gene profiles points out the need to further explore factors involved in the selection of particular epidemic variants with enhanced ability to colonize and persist for extended periods of time.

**Competing interests**

The authors declare that they have no competing interests.

**Authors’ contribution**

AN was responsible for study conception and design, data acquisition and analysis and drafted the manuscript. LP participated in the conception and design, analysis of data and preparation of the manuscript. CV, JP and CM contributed with data acquisition and analysis. TC and GD were implicated in data analysis and preparation of the manuscript. All authors read and approved the final manuscript.

**Acknowledgements**

We thank (in alphabetical order) Anette Hammerum (Statens Serum Institut, Denmark), Se Hyun Kim (Asian Bacterial Bank of the Asia Pacific Foundation for Infectious Diseases), Marie-Hélène Nicolas-Chanoine (Hôpital Beaujon, France), Lee W. Riley (School of Public Health, Berkeley, Canada), Flemming Scheutz (WHO Collaborating Centre for Reference and Research on *Escherichia* and *Klebsiella*, Copenhagen, Denmark), Arnfinn Sundsfjord (Department of Medical Biology, University of Tromsø, Norway), for the strains' gift. We are also grateful to Dr. Martinotti for the gift of *E. coli* CFT073 and Carla Rodrigues for statistical analysis support. This work was supported
Shin J, Kim DH, Ko KS. Comparison ofCTX-M-14- and CTX-M-15-producing Escherichia coli and Klebsiella pneumoniae isolates from patients with bacteremia. J Infect 2011, 63(1):39–47.

Mushatq S, Irfan S, Samma JB, Dourmith M, Pike R, Pitout J, Livermore DM, Woodford N. Phylogenetic diversity of Escherichia coli strains producing NDM-type carbapenemases. J Antimicrob Chemother 2011, 66(1):2002–2005.

Tian GB, Rivera JL, Park YS, Johnson LE, Hingwe A, Adams-Hasducht JM. DoE Sequence type ST405 Escherichia coli isolate producing QepA1, CTX-M-15, and RmtB from Detroit, Michigan. Antimicrob Agents Chemother 2011, 55(8):3966–3967.

Mora A, Blanco M, Lopez C, Marami R, Blanco JE, Alonso MP, Garcia-Garrote F, Dabhi G, Herrera A, Fernandez A, et al. Emergence of clonal groups O1:HNM-D-ST59, O15:H1-D-ST393, O22:H44/HNM-D-ST354, O22b:H4-B2-ST131 and ONT:H24,42-B1-ST101 among CTX-M-14-producing Escherichia coli clinical isolates in Galicia, northwest Spain. Int J Antimicrob Agents 2011, 37(1):16–21.

Hancock V, Ferrieres L, Klemm P. The ferric yersiniabactin uptake receptor FyuA is required for efficient biofilm formation by urinary tract infectious Escherichia coli in human urine. Microbiology 2008, 154(Pt 1):1167–175.

Naves P, Del Prado G, Huvels L, Garcia M, Ruigómez R, Blanco D, Dabhi G, Blanco M, Ponte Mdel C, Soriano F. Correlation between virulence factors and in vitro biofilm formation by Escherichia coli strains. Microb Pathog 2008, 45(2):86–91.

Donelli G, Vuotto C, Cavardis R, Mastrantonio P. Biofilm-growing intestinal anaerobic bacteria, FEMS Immunol Med Microbiol 2012, 65(2):318–325.

Tartof Y, Söllberg OD, Manges AR, Riley LW. Analysis of a uropathogenic Escherichia coli clinical group by multilocus sequence typing. J Clin Microbiol 2005, 43(2):5860–5864.

Trobos M, Christensen H, Sunde M, Nordentoft S, Agerso Y, Simonsen GS, Trobos M, Christensen H, Sunde M, Nordentoft S, Agerso Y, Simonsen GS, Trobos M, Christensen H, Sunde M, Nordentoft S, Agerso Y, Simonsen GS, Trobos M, Christensen H, Sunde M, Nordentoft S, Agerso Y, Simonsen GS. Characterization of sulphonamide-resistant Escherichia coli using comparison of sul2 gene sequences and multilocus sequence typing. Microbiology 2009, 155(Pt 3):831–836.

Queiroz ML, Antunes P, Mourao J, Menquiro V, Machado E, Peixe LV. Characterization of extended-spectrum beta-lactamases, antimicrobial resistance genes, and plasmid content in Escherichia coli isolates from different sources in Rio de Janeiro, Brazil. Diagn Microbiol Infect Dis 2012, 74(1):91–94.

Campos J, Peixe L, Mourão J, Pires J, Silva A, Costa C, Nunes H, Pestana N, Novais C, Antunes P. Are ready-to-eat salads an important vehicle of pathogenic and commensal bacteria resistant to antibiotics? Clin Microbiol Infect 2011, 17(6):5703.

Leffon-Gulvout B, Blanco J, Arambadou M, Mora A, Guize L, Nicholas-Chanone MH. Absence of CTX-M enzymes but high prevalence of clones, including clone ST131, among fecal Escherichia coli isolates from healthy subjects living in the area of Paris, France. J Clin Microbiol 2008, 46(12):3900–3905.

Valverde A, Cantor R, Garcia-Bordia-Marcia MP, Novais A, Galan JC, Alvarez M, de la Cruz F, Baquero F, Coque TM. Spread of bla(CTX-M-14) is driven mainly by IncP plasmids disseminated among Escherichia coli phylogroups A, B1, and D in Spain. Antimicrob Agents Chemother 2009, 53(12):5204–5212.

Novais A, Baquero F, Machado E, Cantón R, Peixe L, Coque TM. International spread and persistence of TEM-24 is caused by the clonality of highly penetrating enterobacteriaceae clones and an IncC2 plasmid containing Tn1696/Tn15 and IS5075-Tn21. Antimicrob Agents Chemother 2010, 54(2):825–834.

Novais A, Viana D, Baquero F, Martinez-Botas J. Cantón R, Coque TM. Contribution of IncFII and broad-host IncA/C and IncN plasmids to the local expansion and diversification of phylogroup B2 Escherichia coli ST131 clones carrying blaCTX-M-15 and qnr51 genes. Antimicrob Agents Chemother 2012, 56(5):2763–2766.

Novais A, Pires J, Ferreira H, Costa L, Montenegro C, Vuotto C, Donelli G, Coque TM, Peixe L. Characterization of globally spread Escherichia coli ST131 isolates (1991 to 2010). Antimicrob Agents Chemother 2012, 56(7):3973–3976.

Juhás M, van der Meer JR, Gaillard M, Harding RM, Hood DW, Crook DW. Genomic islands: tools of bacterial horizontal gene transfer and evolution. FEMS Microbiol Rev 2009, 33(6):757–793.

Mao BH, Chang YF, Scaria J, Chang CC, Chou LW, Tien N, Wu JJ, Tsesng CC, Wang MC, Hsu YM. Identification of Escherichia coli genes associated with urinary tract infections. J Clin Microbiol 2012, 50(2):449–456.

Dias RC, Marangoni DV, Riley LW, Moreira BM. Identification of uropathogenic Escherichia coli clinical group A (CgA) in hospitalised patients. Memorias do Instituto Oswaldo Cruz 2005, 104(3):787–789.
32. Johnson JR, Murray AC, Kuskowski MA, Schubert S, Prete MF, Picard B, Colodner R, Raz R: Distribution and characteristics of Escherichia coli clonal group A. Emerg Infect Dis 2005, 11(1):141–145.

33. Manges AR, Johnson JR, Foxman B, O'Bryan TT, Fullerton KE, Riley LW: Widespread distribution of urinary tract infections caused by a multidrug-resistant Escherichia coli clonal group. N Engl J Med 2001, 345(14):1007–1013.

34. Prats G, Navano F, Mirelis B, Dalmau D, Margall N, Coll P, Stell A, Johnson JR: Escherichia coli serotype O15:K52:H1 as a uropathogenic clone. J Clin Microbiol 2000, 38(1):201–209.

35. Mihaila L, Wyplosz B, Clermont Q, Gary L, Hipeaux MC, Vttecoq D, Dussaix E, Denamur E, Branger C: Probable intrafamily transmission of a highly virulent CTX-M-3-producing Escherichia coli belonging to the emerging phylogenetic subgroup D2 O102-ST405 clone. J Antimicrob Chemother 2010, 65(7):1537–1539.

36. Clermont O, Lavollay M, Vimont S, Deschamps C, Forestier C, Branger C, Denamur E, Arlet G: The CTX-M-15-producing Escherichia coli diffusing clone belongs to a highly virulent B2 phylogenetic subgroup. J Antimicrob Chemother 2008, 61(5):1024–1028.

doi:10.1186/1471-2180-13-144
Cite this article as: Novais et al.: Diversity and biofilm-production ability among isolates of Escherichia coli phylogroup D belonging to ST69, ST393 and ST405 clonal groups. BMC Microbiology 2013 13:144.